Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the
lipid bilayer . The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever . A decade later, the lipid fraction from egg yolk was identified as the component responsible for
this effect , with PEA being the active component . The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory , analgesic , and anticonvulsant  properties. Indeed, these past 15 years have seen a
noteworthy increase in studies dealing with the antiinflammatory actions of PEA . Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
Scienze del Farmaco University of Padova Padova, Italy.
Publication date: May 1, 2012
More about this publication?
CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.